Appili therapeutics announces alignment with fda on development requirements for ati-1801 topical antiparasitic product nda submission

Demonstrated safety and efficacy across multiple phase 2 and phase 3 studies appili provides update on aditxt transaction and encourages shareholders to vote their shares as soon as possible for the november 6, 2024 shareholders meeting halifax, nova scotia, oct. 31, 2024 (globe newswire) -- appili therapeutics inc. (tsx: apli; otcpink: aplif) (the “company” or “appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that the u.s. food and drug administration (“fda”) has provided positive feedback regarding the development strategy for ati-1801, and agreed on the necessary registration package to support a new drug application (“nda”). ati-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.
ATI Ratings Summary
ATI Quant Ranking